Nagata Naoki

kitakyushu general hospital · director

The patient was a 77-year-old woman who visited her local clinic in May 2023 to begin treatment for hypertension. A chest X-ray revealed a nodular shadow in the right lung, and she was referred to our hospital in June. As a result of further examination, in addition to ascending colon cancer with metastatic lung cancer, UICC(#8) Stage IVA, right re...

Background: Capecitabine plus oxaliplatin (CapeOX) is a standard treatment option for advanced gastric cancer (AGC). We conducted a prospective multicenter phase II study to evaluate the efficacy and safety of CapeOX as a first-line therapy for AGC in older patients. Methods: Chemotherapy-naive patients aged ≥ 70 years with AGC were eligible. In...

The 2022 edition of the Guidelines for the Treatment of Colorectal Cancer described rechallenge therapy as a backward treatment for unresectable colorectal cancer, but currently, there is no evidence to support its benefit. We reviewed 6 cases of rechallenge therapy in which tumor marker trends could be followed in our department. Two cases had a r...

A 47-year-old woman complaining of shortness of breath was referred to our hospital from a nearby clinic. Computed tomography (CT) revealed multiple bilateral pulmonary cysts and bilateral pneumothorax, which were more marked on the right. Chest drains were inserted bilaterally, but the pneumothoraxes did not improve. Thus, the pulmonary cyst in th...

348 Background: CapeOX is a standard regimen for treating advanced gastric cancer (AGC). However, limited data are available for its use in the elderly patients. Geriatric assessment (GA) assessment is also considered important other than the age. Therefore, we conducted a multicenter, single-arm, phase II study to evaluate the efficacy and safety...

A 46-year-old man visited our hospital with the chief complaint of a fever of 38.7°C. He thought that the cause was a mass in the right inguinal region that had appeared 6 months earlier and increased thereafter. Excisional biopsy resulted in a diagnosis of lymph node metastasis derived from colorectal cancer. The case was diagnosed as anal canal a...

Many surgical techniques for parastomal hernia have been reported, but none is considered standard. The recurrence rate is lower with mesh than without, and the use of mesh is recommended, but there are many types of mesh. In our department, the laparoscopic Sugarbaker technique has been the first choice, and the Parietex Composite Parastomal Mesh...

An 89-year-old woman developed anal pain in November 2020 and visited a nearby clinic. She was then referred to our hospital in December on suspicion of anal canal cancer. Colonoscopy showed a neoplastic lesion in the anal canal, with neuroendocrine carcinoma on biopsy examination, with atypical ductal epithelial areas in some areas. No distant met...

Although surgical resection is the only available treatment to achieve long-term survival in biliary tract cancer, many cases are often identified at an advanced stage at the time of diagnosis. Radiotherapy may be an alternative option to prolong survival in cases with locally advanced unresectable disease. While there are some reports of long-term...

This multicenter single‐arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC). Additionally, clinical value of the RAS/BRAF mutation status in circulating cell‐free DNA (ccfDNA) was evaluated; this evaluation was measured indepen...

A 74-year-old man visited a clinic with dysphagia and weight loss. Esophagogastroduodenoscopy revealed a tumor over the middle and lower thoracic esophagus, and the patient was referred to our hospital for further examination and treatment. Computed tomography (CT) revealed a 9-cm neoplastic lesion with an irregular ulcer ; however, histopathologic...

Invasive cribriform carcinoma is a rare type of invasive breast carcinoma, and a few cases have been reported. Its features are a cribriform pattern resembling the histological structures of cribriform ductal carcinoma in situ and an excellent prognosis. However, the extent of progress for intraductal extension must be carefully evaluated. Immunohi...

A 55-year-old woman became aware of a tumor on the left side of the head in July, 2020 and was referred to our hospital in September because of its rapid growth. A head CT showed a neoplastic lesion of the skull. A CT from the neck to the pelvis revealed an ascending colon tumor and multiple lesions in the liver, which was suspected as metastasis....

Invasive cribriform carcinoma is a rare type of invasive breast carcinoma, and few cases have been reported. Its features are a cribriform pattern resembling the histological structures of cribriform ductal carcinoma in situ and an excellent prognosis. However, the extent of progress for intraductal extension must be carefully evaluated.

Background The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. Methods Stage II/III colon cancer patients with neuropathies of grade ≤ 1 who relapsed more than 6 months after adjuvant chemotherapy including OX...

In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below.

We report two cases of synchronous double primary cancers, which were composed of prostate cancer accompanied by bone metastasis and colon cancer, within only five months of each other. The first was a 77-year-old man whose ECOG PS was 0. He was referred to our hospital in March 2020 because abdominal CT scan, which was performed at a clinic for th...

The patient was a 66-year-old man who underwent resection of malignant melanoma of the nasal cavity at the Department of Otolaryngology in our hospital in June 2018. After that, he had been followed up by the Department of Otolaryngology and Head and Neck Surgery in the neighboring university hospital. He had local recurrence in the posterior nares...

An 85-year-old woman was referred to the department of plastic surgery of our hospital for detailed examination with a complaint of an enlarged left submandibular lymph node in October 2019. Pathological diagnosis by excisional biopsy showed malignant lymphoma. She was found to have anemia at the time of hospitalization. On further examination, she...

The patient was a 65-year-old man. In October 2020, he visited a nearby clinic doctor with a chief complaint of bloody stools. Colonoscopy revealed a mass lesion in the rectosigmoid colon, and he was referred to the department of internal medicine at our hospital in the same month. After close examination, he was diagnosed with rectosigmoid colon c...

A 67-year-old man was undergoing postoperative follow-up for two colorectal cancers. Laparoscopic partial resection of the small intestine and excisional biopsy of the mesenteric lymph node of the small intestine were performed after neoplastic lesions of the small intestine with distant lymph node metastasis were diagnosed by CT and FDG-PET in Aug...

Purpose: The purpose of this clinical study was to be the first to explore whether ART-123, a recombinant human soluble thrombomodulin, prevents oxaliplatin-induced peripheral neuropathy (OIPN). Methods: This randomized, phase IIa trial enrolled stage II/III colon cancer patients who received adjuvant mFOLFOX6 chemotherapy. Participants were ran...

Lessons learned: A biweekly TAS-102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS-102 plus BEV combination. Biweekly TAS-102 plus BEV combination could reduce unnecessary dose reduction of TAS-102, maintain higher doses, and possibly be effective e...

121 Background: We have conducted the multicenter, phase Ib/II study to assess the activity and safety of biweekly Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) combination for pts with metastatic colorectal cancer (mCRC) who were refractory or intolerant to standard therapies, and the primary endpoint of investigator assessed progression...

Objective: This study aimed to analyze the risk factors for leakage in laparoscopic rectal cancer surgery. Methods: We retrospectively examined 112 patients who underwent anastomosis with the double stapling technique in laparoscopic rectal cancer surgery at our hospital. To identify the risk factors, we analyzed age, sex, body mass index, diabetes...

We report two cases of port site recurrence after laparoscopic colectomy for colorectal cancer. Case 1 : A 73-year-old man was diagnosed with sigmoid colon cancer and received laparoscopic-assisted colectomy. CT scan showed port site recurrence in addition to lung and liver metastases 10 months after laparoscopic colectomy. The patient received en...

A 72-year-old man suddenly developed constipation and suffered a bout of watery diarrhea in small amounts. He was referred to our hospital and diagnosed with stenotic type ischemic colitis of the sigmoid colon and rectum. Abdominal computed tomography showed narrowing of the superior and inferior mesenteric veins, and blood flow from the entire col...

Background: Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal cancer (mCRC). However, the long-term administration of oxaliplatin is associated with peripheral neuropathy (PN). We investigated whether the planned discontinuation of oxaliplatin...

Predicting tumor response prior to starting anti-epidermal growth factor receptor (EGFR) antibody therapy would benefit patients with advanced/metastatic colorectal cancer (mCRC). The present study investigated the association between efficacy of cetuximab treatment and gene polymorphisms of fragment C γ receptor (FcγR) 2A, FcγR3A and EGFR in patie...

This phase II clinical trial compared the efficacy and safety of second-line irinotecan and panitumumab treatment (IRI + Pmab) with that of irinotecan, fluoropyrimidines and panitumumab treatment (control) in patients with KRAS wild-type mCRC. The primary endpoint was progression-free survival. In addition, early predictive markers of treatment eff...

647 Background: Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (Bmab) combination therapy has shown a promising activity with manageable safety profile in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC). The aim of this multicenter, phase Ib/II study was to assess the activity and safety of biweekly FTD/TPI with Bmab c...

The efficacy and safety of the continuous use of panitumumab in first- and second-line treatments for colorectal cancer (CRC) have yet to be determined. Liquid biopsy of circulating tumor DNA is capable of assessing the gene mutation status at several time-points, and could predict the efficacy of ongoing panitumumab treatment. To address these two...

Background: Oxaliplatin and capecitabine (CapeOX) combined with cetuximab is rarely used to treat advanced and metastatic colorectal cancer (mCRC). The present study aimed to clarify the clinical benefits of this treatment regimen when used as a first-line therapy in patients with expanded RAS/BRAF/PIK3CA wild-type mCRC, using the data and tumor sp...

1 Aim Monocarboxylate transporter 4 (MCT4) is a proton pump that exchanges lactate through the plasma membrane. The present study investigated the clinical significance of the expression of MCT4 in patients with right‐ or left‐sided colorectal cancer (CRC). 2 Methods Surgical specimens from 237 CRC patients were immunohistochemically stained with...

PurposeFluorouracil monotherapy, instead of the FOLFOX or FOLFIRI regimen, is administered to patients intolerant to oxaliplatin or irinotecan because of their adverse effects. A prospective clinical trial was designed to evaluate the efficacy and safety of fluorouracil monotherapy combined with panitumumab administered to patients with KRAS wild-t...

Background: The current pooled analysis evaluated the efficacy of Hangeshashinto (TJ-14) in the prevention and/or treatment of chemotherapy-induced oral mucositis (COM) in gastric cancer and colorectal cancer using two prospective, multi-institutional, randomized, double-blind, placebo-controlled phase II trials. Patients and Methods: HANGESHA-G an...

729 Background: FOLFOX therapy, an infusion of 5-fluorouracil (5-FU) with leucovorin in combination with oxaliplatin (OXA), is a common first-line chemotherapy regimen for unresectable, advanced or recurrent colorectal carcinoma (CRC). However, long-term administration of OXA is associated with peripheral neuropathy (PN); decreasing treatment lengt...

TPS886 Background: The mechanisms underlying the acquired resistance of metastatic colorectal cancer (mCRC) against panitumumab treatment is not fully understood. The efficacy and safety of FOLFIRI with panitumumab as the second-line chemotherapy after failure of FOLFOX with panitumumab treatment has yet to be determined. To address these two point...

This meta-analysis will be performed to evaluate the efficacy of Hangeshashinto (TJ-14) in patients with chemotherapy-induced oral mucositis (COM) for gastroenterological cancer. Individual patient–level data from two prospective, double-blind, placebo-controlled randomized trials employing the same regimens using TJ-14 will be collected for this s...

Background: In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer. However, peripheral nerve disorders caused by OXA during mFOLFOX6 therapy can decrease patients' quality of life. OXA can be safely discontinued from a FOL...

The current phase II study investigated the efficacy and safety of biweekly cetuximab combined with standard oxaliplatin-based chemotherapy [infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX-6)] in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Sixty patients with a median age of 64 years (range,...

Background: Despite the comparable clinical benefit of XELOX (capecitabine with oxaliplatin) and FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), the value of XELOX treatment in combination with cetuximab for metastatic colorectal cancer (mCRC) remains largely unknown. Patients and methods: In this clinical trial we evaluated the efficacy a...

Aim: This phase II study assessed the efficacy and toxicity of an intermittent weekly capecitabine regimen in combination with oxaliplatin (XELOX) plus bevacizumab as a first-line treatment of metastatic colorectal cancer (mCRC). Patients and methods: Patients with measurable mCRC who were to receive first-line chemotherapy were enrolled onto th...

Objective: No salvage treatment had been established for metastatic colorectal cancer (mCRC) with mutated KRAS before the emergence of the new drugs regorafenib and TAS-102. We performed a phase II study of third-line chemotherapy with combined bevacizumab and S-1 for mCRC. Methods: Subjects were mCRC patients with mutated KRAS who showed diseas...

Purpose: The aim of this phase II clinical trial was to evaluate the preventive effect of dexamethasone mixing injection for venous pain in patients with colorectal cancer during chemotherapy. Materials and methods: Patients were randomized to receive a 2-h intravenous infusion of oxaliplatin 130 mg/m(2) on day 1 followed by capecitabine 1000 mg...

Background: The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen. Methods: The patients with mCRC wh...

Background The clinical benefit of cetuximab combined with oxaliplatin-based chemotherapy remains under debate. The aim of the present multicenter open-label Phase II study was to explore the efficacy and safety of biweekly administration of cetuximab and mFOLFOX-6 or XELOX as first-line chemotherapy in patients with metastatic colorectal cancer....

A targeted agent combined with chemotherapy is the standard treatment in patients with metastatic colorectal cancer (mCRC). The present phase III study was conducted to compare two doses of bevacizumab combined with irinotecan, 5-fluorouracil/leucovorin (FOLFIRI) in the second-line setting after first-line therapy with bevacizumab plus oxaliplatin-...

Aim: ML18147 showed continued bevcizumab(BEV) with second-line chmotherapy for patients with metastatic colorectal cancer (mCRC) treated with bev plus standard first-line chemotherapy, represents an option for patients with mCRC independent of KRS status. EAGLE study evaluted two doses of bev (10 mg/kg or 5 mg/kg) combined with FOLFIRI in the secon...

Aim: This is a multicenter phase II study to assess the efficacy and toxicity of FOLFIRI treatment agents in full and the influence of UGT1A1*28 polymorphism in Japanese patients with advanced/metastatic colorectal cancer (mCRC). Fifty patients with mCRC participated in this study. Treatment consisted of FOLFIRI (irinotecan; 150 mg/m(2)) as second-...

Oxaliplatin-induced peripheral neurotoxicity (OPN) is frequent and potentially severe, but successful treatment of this condition is still an unmet clinical need. We aimed to determine whether treatment with goshajinkigan (TJ-107), a traditional Japanese medicine, is better than placebo in preventing OPN in patients with advanced or recurrent color...

Unlabelled: Retrospective studies have suggested that UDP-glucuronosyltransferase (UGT)1A1, UGT1A7, and UGT1A9 predict severe toxicity and efficacy of irinotecan-containing regimens. We prospectively evaluated the impact of UGT1A genotypes and haplotypes on severe toxicity and efficacy in patients treated with fluorouracil, leucovorin, and irinote...

Hangeshashinto (TJ-14, a Kampo medicine), which reduces the level of prostaglandin E2 and affects the cyclooxygenase activity, alleviates chemotherapy-induced oral mucositis (COM). We conducted a double-blind, placebo-controlled, randomized comparative trial to investigate whether TJ-14 prevents and controls COM in patients with colorectal cancer....

3516 Background: The phase III ML18147 study (NCT00700102) showed a survival benefit for the continuation of bev after 1st-line bev-containing therapy in pts with mCRC. Continuation of bev beyond disease progression in this setting was approved by the FDA in Jan 2013. In the randomized, phase II SPIRITT study (NCT00418938) assessing 2nd-line treatm...

Purpose: Paclitaxel-cisplatin (TC) combination is effective and well tolerated in patients with unresectable gastric cancer. We investigated the efficacy and safety of TC for locally advanced gastric cancers in a neoadjuvant setting. Methods: Patients received 2-4 courses of paclitaxel (80 mg/m(2)) and cisplatin (25 mg/m(2)) on days 1, 8, and 15...

552 Background: Anti-Epidermal growth factor receptor (EGFR) antibody therapy is expected to be effective in treatment for metastatic colorectal cancer (mCRC) with wild-type KRAS, but for mCRC with mutated KRAS, no salvage treatment has been established. We performed a phase II clinical study on 3rd-line chemotherapy combined bevacizumab with S-1,...

463 Background: Cetuximab and chemotherapy as first-line therapy for patients with KRAS wild type prolong survival. However, COIN trial has not demonstrated the survival benefit of FOLFOX or XELOX and cetuximab therapy. Few data are available on its benefit for patients with KRAS and BRAF wild-type. Methods: The aim of this study was to assess the...

A 94-year-old man was referred to our hospital with a huge rectal GIST, which had been diagnosed seven years earlier by core needle biopsy. CT and PET-CT revealed a bulky mass, 8 cm in diameter, in the presacral space. He refused an abdominoperineal resection, which is essential for large rectal GIST, so we started neoadjuvant treatment with imatin...

Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC.

TPS3642 Background: There has been much controversy about continuation of bevacizumab (BV) with a second-line regimen after progression on a BV-containing first-line regimen. Recently, it was announced that a phase III study (AIO 0504 / ML 18147) met its primary endpoint of overall survival. It means BV-based regimen (5 mg/kg) extends survival when...

567 Background: Oxaliplatin-induced peripheral neuropathy (OPN) continues to be a substantial problem for many cancer patients. In light of the promising data on TJ-107 from a previous pilot study (ASCO-GI, 2009), the present clinical trial was conducted to evaluate its efficacy for the prevention of OPN. To determine whether TJ-107 given as an adj...

481 Background: Survival advantage of second line FOLFIRI plus cetuximab in patients with KRAS wild-type metastatic colorectal cancer has not been well reported. Since mutations in codons 12 and 13 of the KRAS gene predict lack of response to Cetuximab, mutations of V600E BRAF and PI3CA have been controversial. Methods: The aim of this study was to...

The patient is a 62-year-old female who underwent a right hemicolectomy for type-2 ascending colon cancer (moderately-differentiated adenocarcinoma, ss, n0, H0, P0, M0, stage II). Six months after the surgery, a solitary metastatic focus was expressed in the liver S3. Because schizophrenia was present concurrently, tegafur and uracil/folinate (UFT/...

This is a multicenter phase II study to assess the efficacy and toxicity of the 5-FU, leucovorin, and oxaliplatin (FLOX) (SWIFT 3) regimen in Japanese patients with advanced colorectal cancer (CRC). Fifty-two patients were enrolled and evaluated from 12 institutions. The median age was 66 years, with 40.4% of patients with colon cancer and 59.6% wi...

This is the first phase II study to evaluate the efficacy and tolerability of the first-line FOLFIRI, as well as the influence of uridine diphosphate glucuronosyl transferase 1, family polypeptide A1 gene (UGT1A1) 28/6 polymorphism, in Japanese metastatic colorectal cancer patients. Fifty-two patients were enrolled in this study and were administra...

Islet transplantation for the treatment of type 1 diabetes mellitus is limited in its clinical application mainly due to early loss of the transplanted islets, resulting in low transplantation efficiency. NKT cell-dependent IFN-gamma production by Gr-1(+)CD11b(+) cells is essential for this loss, but the upstream events in the process remain undete...

症例は23歳，女性．生後5カ月時に左副腎神経芽腫に対し腫瘍切除，左腎・副腎合併切除術，術後放射線・化学療法が施行された．22歳時に発熱，左側腹部痛あり，近医受診．脾膿瘍と診断され，保存的治療で軽快したが，3カ月後に再発し，当科紹介となった．神経芽腫の再発はなく，脾膿瘍の原因は同定できなかった．原因精査，根治的治療として開腹手術を施行した．脾彎曲部結腸が脾臓・膵尾部・空腸と一塊となっており，同部を切除した．切除標本で結腸に腫瘍性病変を認め，病理組織学的検査で粘液癌，脾臓・膵尾部への直接浸潤と診断された．放射線照射野内に，10年以上の経過後に癌が発生していること，第二癌の病理組織像，発生臓器が第一癌と異なり，さらには結腸粘液癌であることより，放射線誘発大腸癌と考えられた．

This study assessed the efficacy and toxicity of the FOLFOX4 (SWIFT1) and mFOLFOX6 (SWIFT2) regimens in Japanese patients with metastatic colorectal cancer (mCRC). Patients with mCRC were required to have ECOG performance status of 0 to 1, and to have adequate organ function. Two multicenter Phase II studies (SWIFT1/SWIFT2) were conducted in chemot...

Proteus syndrome is an extremely rare congenital disorder that produces multifocal overgrowth of tissue. This report presents a surgical case of a large lipoma in the abdominal wall of a patient with Proteus syndrome. She was diagnosed with Proteus syndrome based on certain diagnostic criteria. The neoplasm increased in size gradually, producing he...

4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) is a novel retinobenzoic acid derivative. The chemopreventive effect and the mechanism of action of TAC-101 were investigated using a rat chemical colon carcinogenesis model. Colon tumors were induced using intra-rectal instillation of N-methyl-N-nitrosourea (MNU) in F344 rats. These rats...

A 34-year-old female woman with lower abdominal pain since early November 2002 was found in abdominal CT to have a well-circumscribed pelvic tumor measuring 10cm in diameter. Under a diagnosis of intrapelvic tumor, we undertook surgical resection, finding a huge tumor of the sigmoid colon serosa, and the huge tumor was resected. Multiple disseminat...

To establish the maximum tolerated dose and dose-limiting toxicity of chemoradiation with paclitaxel (PTX) and cisplatin (CDDP) for patients with local symptoms due to unresectable primary advanced or locally recurrent gastric adenocarcinoma located at left-upper abdomen. Chemotherapy consisted of PTX at escalating doses of 40-80 mg/m(2) per day an...

A 72-year-old woman underwent high anterior resection for rectal cancer. Fifteen minutes after the start of the operation, the pressure on the respiratory tract rose, blood pressure and SpO2 dropped, and skin rash, wheezing and ECG disorder appeared. The anesthesiologist suspected latex anaphylaxis and interrupted the operation. The patient was tre...

A 53-year-old man undergoing Miles operation and systemic chemotherapy (FOLFIRI) for advanced rectal cancer with simultaneous liver metastasis then underwent 6 courses of bevacizumab combined with FOLFOX chemotherapy. The second day after the final administration of bevacizumab, he presented right lower abdominal pain with fever. CT showed inflamma...

A 56-year-old woman underwent FDG-PET screening, which demonstrated delayed-phase uptake in the lower part of the left breast. The findings of mammography, ultrasonography, MRI and cytological examination were compatible with ductal carcinoma in situ (DCIS), but core needle biopsy showed no evidence of malignancy. Therefore, partial resection of th...

This study was performed to assess the efficacy and safety of weekly paclitaxel and cisplatin combination chemotherapy in patients with advanced or recurrent gastric cancer. Patients with advanced or recurrent gastric cancer were required to have ECOG performance status of 0 to 2, to be over 20 years of age, and to have adequate organ function. Pac...